Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, et al. Scientific most cancers advances 2010: annual report on progress in opposition to most cancers from the American Society of Scientific Oncology. J Clin Oncol. 2010;28:5327–47.
Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of sufferers with persistent myeloid leukemia approaches the life expectancy of the overall inhabitants. J Clin Oncol. 2016;34:2851–7.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 suggestions for treating persistent myeloid leukemia. Leukemia. 2020;34:966–84.
Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in sufferers with persistent myeloid leukaemia who’ve maintained full molecular remission for not less than 2 years: the possible, multicentre Cease Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.
Branford S. Why is it important to realize a deep molecular response in persistent myeloid leukemia? Haematologica. 2020;105:2730–7.
Mikhaeel S, Atallah E. SOHO cutting-edge updates and subsequent questions | replace on treatment-free remission in persistent myeloid leukemia (CML). Clin Lymphoma Myeloma Leuk. 2023;23:333–9.
Saußele S, Richter J, Hochhaus A, Mahon FX. The idea of treatment-free remission in persistent myeloid leukemia. Leukemia. 2016;30:1638–47.
Schoenbeck KL, Flynn KE. Well being-related high quality of lifetime of sufferers with persistent myeloid leukemia as measured by patient-reported outcomes: present state and future instructions. Curr Hematol Malig Rep. 2021;16:491–9.
Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, et al. Continual fatigue is an important issue limiting health-related high quality of lifetime of persistent myeloid leukemia sufferers handled with imatinib. Leukemia. 2013;27:1511–9.
Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, et al. Affect of low-grade hostile occasions on health-related high quality of life in grownup sufferers receiving imatinib or nilotinib for newly identified Philadelphia chromosome constructive persistent myelogenous leukemia in persistent section. Curr Med Res Opin. 2014;30:2317–28.
Richter J, Soderlund S, Lubking A, Dreimane A, Lotfi Okay, Markevarn B, et al. Musculoskeletal ache in sufferers with persistent myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821–3.
Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, et al. Change of health-related profiles after Imatinib cessation in persistent section persistent myeloid leukemia sufferers. Leuk Lymphoma. 2016;57:341–7.
Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, et al. Therapy-free remission following frontline nilotinib in sufferers with persistent myeloid leukemia in persistent section: outcomes from the ENESTfreedom examine. Leukemia. 2017;31:1525–31.
Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang M-J, Pinilla-Ibarz J, et al. Evaluation of outcomes after stopping tyrosine kinase inhibitors amongst sufferers with persistent myeloid leukemia. JAMA Oncol. 2021;7:42–50.
Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, et al. Affected person-reported practical outcomes in sufferers with persistent myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Most cancers Inst. 2022;114:160–4.
Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, et al. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) examine, a potential, single-group longitudinal examine in sufferers with persistent myeloid leukemia. BMC Most cancers. 2018;18:359.
Efficace F, Baccarani M. High quality of life enhancements in sufferers with persistent myeloid leukemia after stopping long-term remedy: who can profit probably the most? J Natl Most cancers Inst. 2022;114:9–11.
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor remedy in persistent myeloid leukaemia (EURO-SKI): a prespecified interim evaluation of a potential, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–57.
Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European Cease Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Continual Myeloid Leukemia: Remaining Evaluation and Novel Prognostic Components for Therapy-Free Remission. J Clin Oncol. 2024: 42:1875–80 Jco2301647.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Group for Analysis and Therapy of Most cancers QLQ-C30: a quality-of-life instrument to be used in worldwide medical trials in oncology. J Natl Most cancers Inst. 1993;85:365–76.
Yellen SB, Cella DF, Webster Okay, Blendowski C, Kaplan E. Measuring fatigue and different anemia-related signs with the Practical Evaluation of Most cancers Remedy (FACT) measurement system. J Ache Symptom Manag. 1997;13:63–74.
Fayers PM, Aaronson NK, Bjordal Okay, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC High quality of Life Group. The EORTC QLQ-C30 Scoring Handbook (third Version). Revealed by: European Organisation for Analysis and Therapy of Most cancers, Brussels 2001.
Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Well being-related high quality of life in persistent myeloid leukemia sufferers receiving long-term remedy with imatinib in contrast with the overall inhabitants. Blood. 2011;118:4554–60.
Hinz A, Singer S, Brahler E. European reference values for the standard of life questionnaire EORTC QLQ-C30: Outcomes of a German investigation and a summarizing evaluation of six European common inhabitants normative research. Acta Oncol. 2014;53:958–65.
Cocks Okay, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Proof-based tips for dedication of pattern dimension and interpretation of the European Organisation for the Analysis and Therapy of Most cancers High quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29:89–96.
Laird NM, Ware JH. Random-effects fashions for longitudinal information. Biometrics. 1982;38:963–74.
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” persistent granulocytic leukemia. Blood. 1984;63:789–99.
Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, et al. Time to health-related high quality of life rating deterioration as a modality of longitudinal evaluation for health-related high quality of life research in oncology: do we want RECIST for high quality of life to realize standardization? Qual Life Res. 2015;24:5–18.
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, et al. Imetelstat in sufferers with lower-risk myelodysplastic syndromes who’ve relapsed or are refractory to erythropoiesis-stimulating brokers (IMerge): a multinational, randomised, double-blind, placebo-controlled, section 3 trial. Lancet. 2024;403:248.
Schafer JL, Yucel RM. Computational methods for multivariate linear mixed-effects fashions with lacking values. J Computational Graph Stat. 2002;11:437–57. 2002/06/01
Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival contemplating disease-specific dying in sufferers with persistent myeloid leukemia. Leukemia. 2016;30:48–56.
Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, et al. Which health-related high quality of life points are necessary to sufferers with persistent myeloid leukemia receiving focused therapies and to well being care professionals? : GIMEMA and EORTC High quality of Life Group. Ann Hematol. 2012;91:1371–81.
Hyland KA, Eisel SL, Hoogland AI, Root JC, Bowles Okay, James B, et al. Cognition in sufferers handled with focused remedy for persistent myeloid leukemia: a managed comparability. Leuk Lymphoma. 2023;64:415–23.
Schoenbeck KL, Tummala S, Goyal NG, Smith CC, Shah NP. Cognitive dysfunction related to tyrosine kinase inhibitors in sufferers with CMl in persistent section. Blood. 2020;136:2–3. 2020/11/05/
Kota V, Atallah E. Musculoskeletal ache in sufferers with persistent myeloid leukemia after tyrosine kinase inhibitor remedy cessation. Clin Lymphoma Myeloma Leuk. 2019;19:480–7.
Flynn KE, Atallah E, Lin L, Shah NP, Silver RT, Larson RA, et al. Affected person- and physician-reported ache after tyrosine kinase inhibitor discontinuation amongst sufferers with persistent myeloid leukemia. Haematologica. 2022;107:2641–9.
Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, et al. Longer therapy period and historical past of osteoarticular signs predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol. 2019;187:337–46.
Lou J, Huang J, Wang Z, Wen B, Tu C, Huang W, et al. Continual myeloid leukemia sufferers and treatment-free remission attitudes: a multicenter survey. Affected person Choose Adherence. 2018;12:1025–32.
Efficace F, Iurlo A, Patriarca A, Stagno F, Bee PC, Ector G, et al. Validation and reference values of the EORTC QLQ-CML24 questionnaire to evaluate health-related high quality of life in sufferers with persistent myeloid leukemia. Leuk Lymphoma. 2021;62:669–78.
